CollabRx, Inc. (NASDAQ: CLRX) said it has priced an underwritten public offering of 913,500 shares of its common stock, offered at a public offering price of USD2.00 per share.
Gross proceeds to CollabRx from this offering are expected to be USD1,827,000 before deducting the underwriting discount and other estimated offering expenses payable by CollabRx.
CollabRx anticipates using the net proceeds from the offering for general corporate purposes, including development of their products and services, general and administrative expenses and working capital.
The offering is expected to close on or about June 25, 2014, subject to customary closing conditions
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
CollabRx is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world´s knowledge on genomics-based medicine with specific insights from the nation´s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.